Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Tomophase OCTIS(TM) Receives FDA 510(K) Clearance to Market

December 10, 2010 5:31 am | by Bio-Medicine.Org | News | Comments

BURLINGTON, Mass., Dec. 10, 2010 /- Tomophase Corporation, developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS™) and other devices, announced today that it has received FDA 510(k) clearance to market OCTIS. Tomophase is a leader in the development of OCT...

TOPICS:

Combination Therapy Reduced HER2-positive Breast Cancers

December 10, 2010 4:35 am | by AACR | News | Comments

SAN ANTONIO - A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held...

TOPICS:

Pertuzumab and Trastuzumab Combination Improved Efficacy for Women With HER2-positive Breast Cancer

December 10, 2010 4:34 am | by AACR | News | Comments

SAN ANTONIO - The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.

TOPICS:
Advertisement

Phase III Study Compared Neoadjuvant Therapy with Lapatinib or Trastuzumab for Early Breast Cancer

December 10, 2010 4:34 am | by AACR | News | Comments

SAN ANTONIO - Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer...

TOPICS:

NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study

December 10, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

SANTA CLARA, Calif., Dec. 10, 2010 /- NewCardio, Inc., (OTC Bulletin Board: NWCI ) a cardiovascular diagnostic solutions developer, today presented the results from a blinded drug safety study conducted by the Cardiac Safety Research Consortium (CSRC) to evaluate the performance of...

TOPICS:

Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension

December 10, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Dec. 10, 2010 /- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial...

TOPICS:

HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock

December 10, 2010 4:32 am | by Bio-Medicine.Org | News | Comments

FRAMINGHAM, Mass. and SYDNEY, Dec. 10, 2010 /- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the pricing of a public offering of $125 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf...

TOPICS:

A Magnetic Shortcut to Clinical Trials

December 9, 2010 8:34 pm | by Massachusetts Institute of Technology | News | Comments

Finding effective drug dosages using MRI could accelerate drug development.

TOPICS:
Advertisement

Buprenorphine treatment produces improved outcome for babies born addicted

December 9, 2010 4:37 pm | by EurekAlert | News | Comments

(Vanderbilt University Medical Center) Babies born into the world addicted to drugs because of their mother's dependence on pain medication, or opioids, may be weaned off the substance more comfortably, with a shorter hospital stay and at a reduced cost, if the mother receives a...

TOPICS:

Covidien Receives FDA 510(k) Clearance for the iDrive(TM) Powered Stapling System

December 9, 2010 4:35 pm | by Covidien | News | Comments

Company's first powered stapling system provides precision, control, access and visibility during open surgical procedures NORTH HAVEN, Conn., Dec 02, 2010 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in surgical...

TOPICS:

Covidien Announces the Launch of Three New Platforms for its Puritan Bennett(TM) 840 Ventilators

December 9, 2010 4:34 pm | by Covidien | News | Comments

Puritan Bennett(TM) 840 Neonatal, Universal and Pediatric-Adult Ventilators Deliver Comprehensive Ventilation to a Broad Range of Patients BOULDER, Colo., Dec 09, 2010 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in...

TOPICS:

Community Health offers to buy Tenet for $3B

December 9, 2010 1:46 pm | by The Associated Press | News | Comments

Community Health Systems Inc. is taking its $3 billion cash and stock offer for rival hospital operator Tenet Healthcare Corp. public, in a move to rally shareholder support for the deal.Tenet shares surged nearly 50 percent in aftermarket trading, rising $2.04 to $6.30.Community Health said...

Cigna buys back $300M of senior notes due in 2018

December 9, 2010 1:45 pm | by The Associated Press | News | Comments

CIGNA Corp. said Thursday that it will buy back $300 million worth of senior debt due in 2018.The health insurance company, based in Philadelphia, said that bondholders have until Dec. 15 to offer up their notes.The purchase price will be calculated by adding .45 percent to the yield of the...

New Surgeon General Report on Smoking and Disease Caps Successful Year of Federal Anti-Tobacco Action, AACR Says

December 9, 2010 1:32 pm | by AACR | News | Comments

WASHINGTON, D.C. - The American Association for Cancer Research commends the U.S. Office of the Surgeon General for its continued focus on tobacco, one of most pressing public health issues of our time. The Surgeon General today released a new report, How Tobacco Smoke Causes Disease,...

TOPICS:

Cholera strain evolves new mechanism for causing disease

December 9, 2010 12:33 pm | by EurekAlert | News | Comments

(American Society for Microbiology) New clinical strains of cholera appear to have evolved a distinctly different mechanism to cause the same disease according to research published in the current issue of the online journal mBio.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading